Vaxcyte, Inc. — Director's Dealing 2022

Feb 8, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-12-20

Reporting Person: Fairman Jeff (VP, Research)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-20	Common Stock	M	4469	$1.79	Acquired	10629	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-20	Stock Option (right to buy)	$1.79	M	4469	Disposed	2027-05-17	Common Stock (4469)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	341227	Indirect
Common Stock	50000	Indirect

Footnotes

F1: The shares subject to the option are fully vested and exercisable.